MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Boston Scientific Corp.

Open

BrancheGesundheitswesen

101.09 0.75

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

100.42

Max

101.95

Schlüsselkennzahlen

By Trading Economics

Einkommen

-138M

562M

Verkäufe

352M

4.6B

KGV

Branchendurchschnitt

74.864

57.333

EPS

0.7

Gewinnspanne

12.322

Angestellte

53,000

EBITDA

-41M

1B

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+18.99% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

23. Juli 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-14B

138B

Vorheriger Eröffnungskurs

100.34

Vorheriger Schlusskurs

101.09

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

Boston Scientific Corp. Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

23. Apr. 2025, 12:16 UTC

Ergebnisse
Wichtige Markttreiber

Boston Scientific Shares Higher on Rosy Outlook, 1Q Beats

3. März 2025, 12:35 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific to Buy Rest of SoniVie for Initial $360 Million

5. Feb. 2025, 12:23 UTC

Ergebnisse

Boston Scientific 4Q Profit Up on Strong Cardio Device Sales

23. Apr. 2025, 10:32 UTC

Ergebnisse

Boston Scientific Sees 2Q Reported Sales Up 17.5%-19.5%, Organic Sales Up 13%-15% >BSX

23. Apr. 2025, 10:31 UTC

Ergebnisse

Boston Scientific Sees 2025 Reported Sales Up 15%-17%, Organic Sales Up 12%-14% >BSX

23. Apr. 2025, 10:30 UTC

Ergebnisse

Boston Scientific 1Q EPS 45c >BSX

23. Apr. 2025, 10:30 UTC

Ergebnisse

Boston Scientific 1Q Adj EPS 75c >BSX

23. Apr. 2025, 10:30 UTC

Ergebnisse

Boston Scientific Sees FY Adj EPS $2.87-Adj EPS $2.94 >BSX

23. Apr. 2025, 10:30 UTC

Ergebnisse

Boston Scientific 1Q Sales $4.66B >BSX

23. Apr. 2025, 10:30 UTC

Ergebnisse

Boston Scientific Sees 2Q Adj EPS 71c-Adj EPS 73c >BSX

23. Apr. 2025, 10:30 UTC

Ergebnisse

Boston Scientific Sees 2Q EPS 45c-EPS 47c >BSX

23. Apr. 2025, 10:30 UTC

Ergebnisse

Boston Scientific 1Q Organic Sales Up 18.2% >BSX

23. Apr. 2025, 10:30 UTC

Ergebnisse

Boston Scientific Sees FY EPS $1.86-EPS $1.93 >BSX

3. März 2025, 11:59 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific to Pay Up to Additional $180 Million Upon Achievement of Regulatory Milestone >BSX

3. März 2025, 11:58 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific to Buy Rest of SoniVie for Initial $360 Million >BSX

3. März 2025, 11:58 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific Announces Agreement To Acquire SoniVie Ltd. >BSX

5. Feb. 2025, 21:33 UTC

Ergebnisse

How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat -- IBD

5. Feb. 2025, 15:20 UTC

Ergebnisse

How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat -- IBD

5. Feb. 2025, 11:39 UTC

Ergebnisse

Boston Scientific Sees 1Q Organic Sales Up 14%-16% >BSX

5. Feb. 2025, 11:39 UTC

Ergebnisse

Boston Scientific Sees 1Q Sales Up 17%-19% >BSX

5. Feb. 2025, 11:38 UTC

Ergebnisse

Boston Scientific Sees 2025 Organic Sales Up 10%-12% >BSX

5. Feb. 2025, 11:38 UTC

Ergebnisse

Boston Scientific Sees 2025 Sales Up 12.5%-14.5% >BSX

5. Feb. 2025, 11:37 UTC

Ergebnisse

Boston Scientific 4Q Organic Sales Up 19.5% >BSX

5. Feb. 2025, 11:37 UTC

Ergebnisse

Boston Scientific 4Q Adj EPS 70c >BSX

5. Feb. 2025, 11:37 UTC

Ergebnisse

Boston Scientific Sees FY EPS $1.86-EPS $1.93 >BSX

5. Feb. 2025, 11:37 UTC

Ergebnisse

Boston Scientific 4Q Sales $4.56B >BSX

5. Feb. 2025, 11:37 UTC

Ergebnisse

Boston Scientific Sees FY Adj EPS $2.80-Adj EPS $2.87 >BSX

5. Feb. 2025, 11:37 UTC

Ergebnisse

Boston Scientific Sees 1Q Adj EPS 66c-Adj EPS 68c >BSX

5. Feb. 2025, 11:37 UTC

Ergebnisse

Boston Scientific Sees 1Q EPS 43c-EPS 45c >BSX

5. Feb. 2025, 11:37 UTC

Ergebnisse

Boston Scientific 4Q EPS 38c >BSX

Peer-Vergleich

Kursveränderung

Boston Scientific Corp. Prognose

Kursziel

By TipRanks

18.99% Vorteil

12-Monats-Prognose

Durchschnitt 120.35 USD  18.99%

Hoch 135 USD

Tief 110 USD

Basierend auf 23 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Boston Scientific Corp. – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

23 ratings

22

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

95.25 / 102.37Unterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Mittelfristig

Strong Bearish Evidence

Langfristig

No Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.